Unknown

Dataset Information

0

Targeting intracellular p-aminobenzoic acid production potentiates the anti-tubercular action of antifolates.


ABSTRACT: The ability to revitalize and re-purpose existing drugs offers a powerful approach for novel treatment options against Mycobacterium tuberculosis and other infectious agents. Antifolates are an underutilized drug class in tuberculosis (TB) therapy, capable of disrupting the biosynthesis of tetrahydrofolate, an essential cellular cofactor. Based on the observation that exogenously supplied p-aminobenzoic acid (PABA) can antagonize the action of antifolates that interact with dihydropteroate synthase (DHPS), such as sulfonamides and p-aminosalicylic acid (PAS), we hypothesized that bacterial PABA biosynthesis contributes to intrinsic antifolate resistance. Herein, we demonstrate that disruption of PABA biosynthesis potentiates the anti-tubercular action of DHPS inhibitors and PAS by up to 1000 fold. Disruption of PABA biosynthesis is also demonstrated to lead to loss of viability over time. Further, we demonstrate that this strategy restores the wild type level of PAS susceptibility in a previously characterized PAS resistant strain of M. tuberculosis. Finally, we demonstrate selective inhibition of PABA biosynthesis in M. tuberculosis using the small molecule MAC173979. This study reveals that the M. tuberculosis PABA biosynthetic pathway is responsible for intrinsic resistance to various antifolates and this pathway is a chemically vulnerable target whose disruption could potentiate the tuberculocidal activity of an underutilized class of antimicrobial agents.

SUBMITTER: Thiede JM 

PROVIDER: S-EPMC5131483 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting intracellular p-aminobenzoic acid production potentiates the anti-tubercular action of antifolates.

Thiede Joshua M JM   Kordus Shannon L SL   Turman Breanna J BJ   Buonomo Joseph A JA   Aldrich Courtney C CC   Minato Yusuke Y   Baughn Anthony D AD  

Scientific reports 20161201


The ability to revitalize and re-purpose existing drugs offers a powerful approach for novel treatment options against Mycobacterium tuberculosis and other infectious agents. Antifolates are an underutilized drug class in tuberculosis (TB) therapy, capable of disrupting the biosynthesis of tetrahydrofolate, an essential cellular cofactor. Based on the observation that exogenously supplied p-aminobenzoic acid (PABA) can antagonize the action of antifolates that interact with dihydropteroate synth  ...[more]

Similar Datasets

| S-EPMC10948109 | biostudies-literature
| S-EPMC6045447 | biostudies-literature
| S-EPMC1246807 | biostudies-literature
| S-EPMC8259857 | biostudies-literature
| S-EPMC10786749 | biostudies-literature
| S-EPMC1855612 | biostudies-literature
| S-EPMC7408260 | biostudies-literature
| S-EPMC2669212 | biostudies-literature
| S-EPMC6412293 | biostudies-literature
| S-EPMC7287914 | biostudies-literature